IgA Nephropathy Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast Segmented By Test (Blood Test, Urine Test, Kidney Biopsy, Iothalamate Clearance Test, Others), By Treatment Type (Corticosteroids, Immunosuppressive Drugs, ACE Inhibitors And ARBs, Diet Change, Therapy), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 173.75 Million
CAGR (2026-2031)	5.61%
Fastest Growing Segment	Urine Test
Largest Market	North America
Market Size (2031)	USD 241.08 Million

Market Overview

The Global IgA Nephropathy Disease Treatment Market will grow from USD 173.75 Million in 2025 to USD 241.08 Million by 2031 at a 5.61% CAGR. IgA Nephropathy treatment encompasses specialized pharmacotherapies, including corticosteroids, immunosuppressants, and emerging targeted agents such as endothelin receptor antagonists, designed to mitigate proteinuria and delay the progression to end-stage renal disease. The market is primarily propelled by the rising global incidence of autoimmune kidney conditions and an intensified regulatory focus on orphan drug designations, which incentivizes pharmaceutical investment in disease-modifying interventions. These fundamental drivers are distinct from transient market trends, as they reflect structural shifts in clinical demand and approval frameworks that underpin sustainable industry expansion.

However, a significant challenge impeding market proliferation is the high rate of delayed diagnosis, as the frequently asymptomatic nature of the condition often leads to missed therapeutic windows and reduced treatment efficacy. This diagnostic latency significantly restricts the addressable patient pool for early-stage therapies. According to the American Kidney Fund in 2025, IgA nephropathy affects around 200,000 people in the United States, a statistic that underscores the substantial yet often underdiagnosed patient population requiring accessible long-term management strategies.

Key Market Drivers

The surge in novel drug approvals and commercial launches serves as a primary catalyst for market expansion, marking a transition from supportive care to targeted disease modification. Regulatory agencies have accelerated the pathway for therapies that specifically address the underlying pathogenesis of the condition, resulting in immediate commercial uptake and revenue generation for approved agents. This shift is quantified by the market performance of newly authorized treatments which are rapidly gaining traction among nephrologists. According to Travere Therapeutics, October 2024, in the 'Travere Therapeutics Reports Third Quarter 2024 Financial Results', the company achieved net product sales of $35.6 million for FILSPARI, reflecting the strong adoption of non-immunosuppressive therapies in the commercial setting. This revenue trajectory validates the willingness of healthcare systems to reimburse premium-priced agents that demonstrate the ability to preserve kidney function and delay dialysis.

Strategic pharmaceutical partnerships and large-scale acquisitions further propel the sector as major industry players invest heavily to secure promising clinical assets. This consolidation activity underscores the high value placed on late-stage biologics capable of addressing the autoimmune components of the condition, driving valuation benchmarks upward. According to Vertex Pharmaceuticals, April 2024, in the 'Vertex to Acquire Alpine Immune Sciences', the company entered a definitive agreement to acquire Alpine for approximately $4.9 billion in cash to access povetacicept, a dual antagonist of BAFF and APRIL. Such substantial capital allocation accelerates the development timeline for next-generation immunotherapies. Furthermore, clinical efficacy remains the critical success factor for these investments; according to Novartis, in 2024, the Phase III APPLAUSE-IgAN analysis demonstrated that Fabhalta achieved a 44% reduction in proteinuria at nine months compared to placebo, establishing a rigorous efficacy standard for future market entrants.

Download Free Sample Report

Key Market Challenges

The significant rate of delayed diagnosis constitutes a critical impediment to the growth of the Global IgA Nephropathy Disease Treatment Market. Because the condition often develops without noticeable symptoms, patients frequently miss the optimal therapeutic window for early-stage interventions, which are the primary focus of recent pharmaceutical investments. This diagnostic latency reduces the practical size of the addressable market, as clinicians cannot prescribe disease-modifying pharmacotherapies to unidentified patients. Consequently, the commercial uptake of high-value targeted agents is artificially suppressed, limiting the return on investment for drug developers and slowing the overall trajectory of industry expansion.

This issue of underdiagnosis is quantified by the high prevalence of unacknowledged renal conditions which directly correlates to the asymptomatic nature of IgA nephropathy. According to the National Kidney Foundation, in 2024, approximately 90% of the 37 million adults living with chronic kidney disease in the United States were unaware of their diagnosis. Since IgA nephropathy is a common underlying cause of this broader disease burden, this statistic highlights a massive pool of patients who require treatment but are currently inaccessible to the market. This prevalent lack of awareness directly hampers market proliferation by preventing the timely initiation of long-term management strategies.

Key Market Trends

The market is increasingly prioritizing a shift towards targeted B-cell immunomodulators to address the fundamental pathogenesis of IgA nephropathy by inhibiting the production of galactose-deficient IgA1. Unlike broad-spectrum immunosuppression, these novel agents specifically disrupt the survival signals of antibody-producing plasma cells, thereby preventing the formation of nephrotoxic immune complexes that drive glomerular inflammation. This mechanism-centric approach is validating the potential for long-term disease stabilization beyond mere symptom control, as developers focus on blocking B-cell activating factors. According to Vera Therapeutics, October 2024, in the 'Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study', the administration of atacicept resulted in a 66% reduction in galactose-deficient IgA1 alongside the stabilization of kidney function, confirming the clinical viability of targeting the BAFF and APRIL pathways to mitigate disease progression.

Simultaneously, there is a decisive focus on oral formulations for chronic disease management, driven by the necessity for patient-centric regimens that enhance adherence over decades of treatment. Pharmaceutical developers are engineering oral therapeutics with advanced delivery systems, such as targeted delayed-release mechanisms, which concentrate active ingredients in the ileum to minimize systemic side effects while maximizing local efficacy. This transition towards convenient, self-administered therapies is rapidly reshaping prescription patterns as healthcare providers seek to reduce the logistical burden associated with infusion-based biologics. According to Calliditas Therapeutics, August 2024, in the 'Interim Report January to June 2024', net sales for TARPEYO amounted to SEK 493.4 million for the second quarter of 2024, underscoring the substantial commercial uptake of oral agents capable of delivering precise immunomodulation.

Segmental Insights

The Urine Test segment currently stands as the fastest-growing category within the Global IgA Nephropathy Disease Treatment Market, primarily driven by the increasing demand for non-invasive methods to monitor therapeutic response. Regulatory authorities, including the US FDA, have validated proteinuria reduction as a key surrogate endpoint for clinical trials, fostering a strong reliance on regular urine analysis to evaluate drug efficacy. This trend significantly reduces the need for invasive biopsies and supports continuous patient monitoring, thereby accelerating the adoption of urine testing protocols across clinical practices globally.

Regional Insights

North America maintains a leading position in the Global IgA Nephropathy Disease Treatment Market, driven by advanced healthcare infrastructure and the widespread availability of diagnostic testing. The region hosts several key pharmaceutical companies dedicated to nephrology research and drug development. Moreover, the U.S. Food and Drug Administration (FDA) offers clear regulatory pathways that facilitate the introduction of new treatments. Comprehensive reimbursement coverage further supports market expansion by ensuring patients can access necessary therapies. These elements collectively establish North America as the central hub for market activity.

Recent Developments

• In September 2024, Travere Therapeutics announced that the U.S. Food and Drug Administration granted full approval for Filspari (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy who are at risk of disease progression. This decision converted the drug's previous accelerated approval to full approval based on long-term confirmatory results from the Phase 3 PROTECT study. The trial data showed that Filspari significantly preserved kidney function over two years compared to an active control. This milestone established the medication as a foundational, non-immunosuppressive therapy for patients managing this rare, progressive kidney disease.
• In August 2024, Novartis received accelerated approval from the U.S. Food and Drug Administration for Fabhalta (iptacopan) for the reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. This regulatory decision marked Fabhalta as the first and only complement inhibitor approved for this specific indication. The approval was supported by interim data from the Phase III APPLAUSE-IgAN study, which demonstrated a clinically meaningful reduction in proteinuria compared to placebo. Novartis continued to evaluate the drug's ability to slow kidney function decline in ongoing studies to support traditional approval.
• In July 2024, Biogen Inc. finalized its acquisition of Human Immunology Biosciences (HI-Bio) to expand its immunology portfolio. The deal involved an upfront payment of $1.15 billion and potential milestone payments of up to $650 million. The acquisition centered on HI-Bio’s lead asset, felzartamab, a fully human anti-CD38 monoclonal antibody being developed for severe immune-mediated diseases, including IgA nephropathy. Clinical studies had shown that felzartamab effectively depleted CD38+ cells, offering a promising therapeutic approach. Biogen aimed to leverage its global development infrastructure to advance felzartamab into late-stage trials for rare renal conditions.
• In May 2024, Vertex Pharmaceuticals Incorporated completed its acquisition of Alpine Immune Sciences, Inc. for approximately $4.9 billion in cash. This strategic transaction provided Vertex with access to Alpine's lead molecule, povetacicept, a highly potent dual antagonist of BAFF and APRIL that had demonstrated best-in-class potential for the treatment of IgA nephropathy. The acquisition was unanimously approved by the boards of directors of both companies and aligned with Vertex's strategy to develop transformative medicines for serious diseases in specialty markets. The addition of Alpine's protein engineering and immunotherapy capabilities significantly bolstered Vertex's pipeline in kidney diseases.

Key Market Players

• Travere Therapeutics Inc
• Calliditas Therapeutics AB
• Omeros Pharma Corporation
• Novartis Pharmaceuticals
• Chinook Therapeutics, Inc.
• Vera Therapeutics, Inc.
• Merck KGaA
• Reata Pharmaceuticals, Inc.
• Ionis Pharmaceuticals
• Apellis Pharmaceuticals

By Test	By Treatment Type	By Region
Blood Test Urine Test Kidney Biopsy Iothalamate Clearance Test Others	Corticosteroids Immunosuppressive Drugs ACE Inhibitors And ARBs Diet Change Therapy	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global IgA Nephropathy Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• IgA Nephropathy Disease Treatment Market, By Test:

• Blood Test
• Urine Test
• Kidney Biopsy
• Iothalamate Clearance Test
• Others

• IgA Nephropathy Disease Treatment Market, By Treatment Type:

• Corticosteroids
• Immunosuppressive Drugs
• ACE Inhibitors And ARBs
• Diet Change
• Therapy

• IgA Nephropathy Disease Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE